First safety test of a drug given straight into brain tumors
Original title: EGFR-targeted antibody-toxin conjugate in recurrent glioma: a phase 1 trial.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was an early test in people to check safety and dose, not an approved treatment.
The short version
Doctors put a new drug right inside brain tumors to see if it was safe.
What was studied. Doctors tested a new drug called D2C7-ATC in 81 people whose glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary had come back. Each person got one infusion sent straight into the tumor. The main goal was to check safety and pick a dose.
What they found. Most side effects linked to the drug were mild or moderate (67%). At the highest dose, four people had side effects bad enough to stop the dose from going higher. Among 72 people with one type of glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary, survival was 7.9 months. Eight people died during the trial, and none of those deaths came from the drug.
What this means, and what it doesn't
What it could mean: The drug was mostly tolerated well, so the team could choose a dose for the next trial. Some people lived longer than others. Tests on their tumor and blood may help explain why.
What it doesn't mean: This does not mean the drug works, and it is not a cure. This was an early safety study at one hospital, with no comparison group. It is still far from everyday care, and you cannot get this drug outside a trial.
Source: PubMed, October 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.